MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients
MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients
On Tuesday, MAIA Biotechnology Inc (NASDAQ:MAIA) announced treatment updates from its Phase 2 THIO-101 trial of THIO sequenced with Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) cemiplimab (Libtayo) for advanced non-small-cell-lung-cancer patients who failed two or more standard-of-care therapy regimens.
週二，MAIA Biotechnology Inc（納斯達克股票代碼：MAIA）宣佈了其使用再生元製藥公司（納斯達克股票代碼：REGN）cemiplimab（Libtayo）測序的THIO的2期 THIO-101 試驗的最新治療方法，該試驗適用於兩種或更多標準護理方案失敗的晚期非小細胞肺癌患者。
The trial's therapeutic regimen is cycled every three weeks, with THIO 180mg administered in 60mg incremental doses on days 1, 2 and 3, followed by immune activation on day 4 (no dosing), and cemiplimab 350mg administered on day 5.
該試驗的治療方案每三週循環一次，在第1、2和3天以60mg的增量劑量給藥THIO 180mg，然後在第4天進行免疫激活（無劑量），在第5天給予塞米普利單抗350mg。
As of the latest clinical cutoff date, June 12, 2024:
截至最新的臨床截止日期，即2024年6月12日：
- Six patients remain on treatment following at least 12 months of therapy.
- Treatment with THIO followed by cemiplimab has been well tolerated throughout the trial, with much lower toxicity than standard-of-care treatments.
- Continuing treatment past 12 months demonstrates safety, efficacy and ongoing benefit from MAIA's novel telomere targeting NSCLC therapy.
- 六名患者在至少12個月的治療後仍在接受治療。
- 在整個試驗過程中，先使用THIO進行cemiplimab治療，耐受性良好，毒性遠低於標準護理療法。
- 過去12個月的持續治療表明，MAIA的新型端粒靶向非小細胞肺癌療法具有安全性、有效性和持續益處。
"Our longest treated patient so far has completed 21 cycles of THIO sequenced with a CPI, and six patients who have crossed the 12-month survival follow-up are continuing the treatment," said Vlad Vitoc, chairman and chief executive officer of MAIA.
MAIA董事長兼首席執行官弗拉德·維托克說：“迄今爲止，我們接受治療時間最長的患者已經完成了按CPI測序的21個THIO週期，還有6名超過12個月存活隨訪的患者正在繼續治療。”
In June, MAIA Biotechnology shared new efficacy data from its Phase 2 THIO-101 study of THIO.
6月，MAIA Biotechnology分享了其針對THIO的2期 THIO-101 研究的新療效數據。
Updated results show a favorable overall response rate (ORR) of 38% and a disease control rate (DCR) of 85% from THIO + CPI in third-line treatment:
最新結果顯示，在三線治療中，THIO + CPI的總體緩解率（ORR）爲38％，疾病控制率（DCR）爲85％：
- The disease control rate (DCR) was 85% for THIO vs. standard of care DCR of 25–35% for chemotherapy.
- 65% of patients crossed the 5.8-month overall survival (OS) threshold.
- 85% of patients crossed the 2.5-month progression-free survival (PFS) threshold.
- Median survival follow-up time is currently 9.1 months (n=20)
- THIO的疾病控制率（DCR）爲85％，而化療的標準護理DCR爲25-35％。
- 65% 的患者超過了 5.8 個月的總存活率 (OS) 閾值。
- 85% 的患者超過了 2.5 個月的無進展存活率 (PFS) 閾值。
- 目前，中位生存隨訪時間爲 9.1 個月（n=20）
Price Action: MAIA stock is down 14.25% at $3.31 at last check Tuesday.
價格走勢：在週二的最後一次檢查中，MAIA股價下跌14.25％，至3.31美元。
- Axsome Therapeutics' CNS Portfolio Poised for Major Growth – Analyst Predicts Strong Future.
- Axsome Therapeutics的中樞神經系統投資組合有望實現重大增長——分析師預測前景光明。
Image created using artificial intelligence via Midjourney.
通過 Midjourney 使用人工智能創建的圖像。